TransMedics Reports Strong Q4 & FY25 Results, Projects 20-25% Revenue Growth in 2026

summarizeSummary

TransMedics Group reported strong Q4 and full-year 2025 financial results, including significant revenue growth and a positive outlook for 2026, driven by increased adoption of its OCS program.

check_boxKey Events

• Strong Revenue Growth Reported

  Total revenue for Q4 2025 increased 32% to $160.8 million, and full-year 2025 revenue grew 37% to $605.5 million, driven by increased OCS utilization and NOP service revenue.

• Significant Net Income Boosted by Tax Benefit

  Net income for Q4 2025 was $105.4 million ($2.62 per diluted share) and for full-year 2025 was $190.3 million ($4.87 per diluted share), including a one-time tax benefit of approximately $83 million from the release of a deferred tax asset valuation allowance.

• Robust 2026 Revenue Guidance Issued

  The company expects total revenue for full-year 2026 to be in the range of $727 million to $757 million, representing 20% to 25% growth compared to 2025.

• Increased OCS Case Utilization

  TransMedics completed 5,139 U.S. OCS cases in full-year 2025, a 38% increase compared to 2024, indicating strong adoption of its organ transplant technology.

auto_awesomeAnalysis

The filing details TransMedics Group's robust financial performance for the fourth quarter and full year 2025, marked by substantial revenue growth and increased utilization of its Organ Care System (OCS). While net income was significantly boosted by a one-time tax benefit from the release of a deferred tax asset valuation allowance, the underlying operational results demonstrate strong execution. The company's 2026 revenue guidance projects continued growth, reinforcing a positive outlook for its core business and expansion initiatives, including recent FDA approvals and international market entry plans.